Oral Acetazolamide for drug related weight gai

Not Applicable

Completed

• Conditions: Health Condition 1: F209- Schizophrenia, unspecified

• Registration Number: CTRI/2019/05/018884
• Lead Sponsor: Anupama Priyamkari

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Completion: 2020-11-23
• Last Update Posted: 24 November 2021

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 34

Inclusion Criteria

Out patients or in patients diagnosed as schizophrenia, schizoaffective disorder, delusional disorder, psychosis NOS, Non organic psychosis diagnosed using MINI PLUS

Both males and females

18 â?? 60 years of age

Patients who are treated with Risperidone or Olanzepine

Patients who are drug naïve, off medication for atleast 6 months or have been on psychotropic medications for less than 1 month.

Without any co-morbid psychiatric illness other than nicotine use

Exclusion Criteria

Persons on Acetazolamide for any medical reasons.

No known medical conditions in which acetazolamide is contraindicated like hyperchloremic acidosis, hypokalaemia, hyponatremia, adrenal insufficiency, impaired kidney function, hypersensitivity to acetazolamide or other sulphonamides, liver diseases.

Pregnancy, lactation

Sub normal intelligence

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
To test the effect of Acetazolamide on weight induced by AntipsychoticsTimepoint: 8 weeks

Secondary Outcome Measures

Name	Time	Method
To assess in Brief Psychiatric Rating Scale score on patients receiving acetazolamideTimepoint: 8 weeks